H.C. Wainwright initiated coverage of Actuate Therapeutics (ACTU) with a Buy rating and $20 price target Actuate is a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback